GENEDRIVE ORD 1.5P overview

RiverFort is pleased to announce that it has arranged an Equity Prepayment Facility for up to £5 million (the "Facility") with Genedrive plc (LSE: GDR) (“Genedrive” or the “Company”), the point of care molecular diagnostics company, with an initial drawn amount of £2 million and committed capital advances of up to £3 million in 10 monthly instalments of £300,000 from 30 May 2023 which may be drawn down by the Company at its election. The Facility and the Company's existing cash...

Hardman & Co Research Hardman & Co Research: genedrive plc (GDR): Western market progress but developing markets difficult 05-Feb-2020 / 07:15 GMT/BST Hardman & Co Res earch : Western market progress but developing markets difficult Genedrive plc (GDR) is a commercial-stage biotech focused on point-of-care molecular diagnostics. Its Genedrive (R) molecular diagnostic platform offers low-cost, simple-to-use devices for highly sensitive and specific testing. The rapid analysis of samples aids...

Hardman & Co Research Hardman & Co Research: genedrive plc (GDR): Regulatory hurdle leaped: hearing loss assay 21-Nov-2019 / 12:30 GMT/BST Hardman & Co Res earch : Regulatory hurdle leaped: hearing loss assay genedrive plc (GDR) is a commercial-stage company focused on point-of-care molecular diagnostics. Its Genedrive (R) molecular diagnostic platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specificity. Rapid analysis of...

Hardman & Co Research Hardman & Co Research: genedrive plc (GDR): Acceleration of news flow expected 28-Oct-2019 / 07:30 GMT/BST Hardman & Co Res earch : Acceleration of news flow expected genedrive plc (GDR) is a commercial-stage company focused on point-of-care molecular diagnostics. Its Genedrive (R) molecular diagnostic platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specificity. Rapid analysis of samples aids...

Hardman & Co Research Hardman & Co Research: genedrive plc (GDR): Hepatitis C market frustrations 18-Jul-2019 / 07:30 GMT/BST Hardman & Co Research: Hepatitis C market frustrations genedrive plc (GDR) is a commercial-stage company focused on point-of-care molecular diagnostics. Its Genedrive(R) molecular diagnostic platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specificity in the diagnosis of infectious diseases. Rapid...

Hardman & Co Research Hardman & Co Research: genedrive plc (GDR): First commercial sales in new focus area: bio-threats 08-Apr-2019 / 10:53 GMT/BST Hardman & Co Research: First commercial sales in new focus area: bio-threats genedrive plc (GDR) is a commercial-stage company focused on point-of-care (PoC) molecular diagnostics. Its Genedrive(R) molecular diagnostic platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and...

Hardman & Co Research Hardman & Co Research: genedrive plc (GDR): Accelerating into fiscal 2019 with first sales 11-Dec-2018 / 07:15 GMT/BST Hardman & Co: Accelerating into fiscal 2019 with first sales genedrive plc (GDR) is a commercial-stage company focused on point-of-care molecular diagnostics. Its Genedrive(R) molecular diagnostic testing platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specificity in the diagnosis...

For release: 29 November genedrive plc ("genedrive" or the "Company") AbbVie sponsored REACH study for the use of Genedrive HCV assay in pharmacies genedrive plc (AIM: GDR), the near patient molecular diagnostics company, today announces that it will participate in an international multicentre trial (‘REACH’) to assess the impact of out-reach HCV diagnostics and therapy in a pharmacy setting versus conventional treatment pathways. The study, led by Prof. John Dillon, Professor of Hepatology...